Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Epidemiology of treatment resistant depression among major depressive disorder patients in Israel

Open access
Sharman Moser, Sarah, Chodick, Gabriel, Gelerstein, Shulamit, Barit Ben David, Nava, Shalev, Varda, Stein-Reisner, Orit · 2022 · BMC Psychiatry

Abstract

Introduction: Major depressive disorder (MDD) is one of the most common mental disorders worldwide, estimated to affect 10–15% of the population per year. Treatment resistant depression (TRD) is estimated to affect a third of these patients who show difficulties in social and occupational function, decline of physical health, suicidal thoughts and increased health care utilization. We describe the prevalence of MDD, TRD and associated healthcare resource utilization in Maccabi Healthcare Services (MHS), a 2.5 million-member state-mandated health service in Israel. Methods: All MHS members with an MDD diagnosis were identified within the years 2017–2018 and prevalence assessed by age, sex and TRD. To assess the incidence of MDD, members aged 18–65 years at the start of any MDD episode were identified between 1 st January 2016 and 31 st May 2018 with at least one systemic first-line antidepressant treatment within three months before or after the initial episode. Treatment patterns, time on first-line treatment, and healthcare resource utilization were compared by TRD. Results: A total of 4960 eligible MDD patients were identified (median age = 51 years, 65% female), representing a period prevalence of 0.218%, and of those, a high proportion of patients received drug treatment (92%). Among incident MDD cases (n = 2553), 24.4% had TRD. Factors associated with TRD included increasing age and personality disorder. Median time on treatment was 3.7 months (longer for those without TRD than those with) and 81.9% of patients purchased more than one month’s supply of therapy. In the year after index, patients with TRD had a significant increased number of visits to primary care physicians, psychiatrists, emergency room visits, general hospitalizations, and psychiatric hospitalizations. Conclusion: Our study shows that prevalence of MDD in Israel is low compared to other countries, however once diagnosed, patients' are likely to receive drug treatment. Among patients diagnosed with MDD, the proportion of TRD is similar to other countries, increases with age and is associated with increased healthcare utilization, therefore should be a focus of continued research for finding effective long term treatment options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-022-04184-8

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Age-specific period prevalence of patients with major depressive disorder by sex for the period 2017–2018, per 100,000 population, n = 4960
Fig. 1 Age-specific period prevalence of patients with major depressive disorder by sex for the period 2017–2018, per 100,000 population, n = 4960CC BY · PubMed Central
Fig. 2 Age-specific period prevalence of all patients with major depressive disorder by treatment resistant depression for the period 2017–2018, by relative distribution of the prevalent cohort, n = 4960. TRD, treatment resistant depression; L1, first-line treatment
Fig. 2 Age-specific period prevalence of all patients with major depressive disorder by treatment resistant depression for the period 2017–2018, by relative distribution of the prevalent cohort, n = 4960. TRD, treatment resistant depression; L1, first-line treatmentCC BY · PubMed Central
Fig. 3 Age-specific period prevalence of patients with major depressive disorder by first-line treatment for those who received treatment for the period 2017–2018, by relative distribution of the prevalent cohort, n = 4596. TCA, tricyclic antidepressants; SSRI, selective serotonin reuptake inhibitors
Fig. 3 Age-specific period prevalence of patients with major depressive disorder by first-line treatment for those who received treatment for the period 2017–2018, by relative distribution of the prevalent cohort, n = 4596. TCA, tricyclic antidepressants; SSRI, selective serotonin reuptake inhibitorsCC BY · PubMed Central
Fig. 4 Time on treatment (months) on first-line treatment for patients in the incident study cohort (patients with the start of any major depressive disorder episode within the study period, 1/1/2016–31/5/2018), n = 2553. (Other monotherapy comprised: 39.1% venlafaxine, 21.5% duloxetine, 10.1% vortioxetine, 9.2% bupropion, 8.4% mirtazapine, 3.9% milnacipran). TCA tricyclic antidepressants, SSRI selective serotonin reuptake inhibitors
Fig. 4 Time on treatment (months) on first-line treatment for patients in the incident study cohort (patients with the start of any major depressive disorder episode within the study period, 1/1/2016–31/5/2018), n = 2553. (Other monotherapy comprised: 39.1% venlafaxine, 21.5% duloxetine, 10.1% vortioxetine, 9.2% bupropion, 8.4% mirtazapine, 3.9% milnacipran). TCA tricyclic antidepressants, SSRI selective serotonin reuptake inhibitorsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. (APA) APA. Practice guidelines for the treatment of patients with major depressive disorder, 3rd edition. 2010 [Available from: http://psychiatryonline.org/guidelines.

Cited by

See all 27

Metadata

Authors
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O.
Affiliations
  • Tel Aviv University (IL)
  • Maccabi Healthcare Services (IL)
Venue
BMC Psychiatry
Published
2022-08-11
Volume
22
Issue
1
Pages
541-541
ISSN
1471-244X (ISSN-L)
OpenAlex
W4290991902
Cited by
23
References
63
Citations by year
2026: 4 · 2025: 4 · 2024: 8 · 2023: 7
FWCI
2.84
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
treatment-resistant depression, major depressive disorder, prevalence, healthcare resource utilization, time on treatment, personality disorders, age as risk factor, psychiatric hospitalization, emergency department visits, Maccabi Healthcare Services, Israel
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Female, Humans, Israel, Male, Middle Aged, Retrospective Studies, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. https://app.cochat.ai/papers/10.1186/s12888-022-04184-8
The paper
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022). Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. BMC Psychiatry. https://doi.org/10.1186/s12888-022-04184-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.